Please use this identifier to cite or link to this item: https://doi.org/10.1371/journal.pntd.0005289
DC FieldValue
dc.titleThe Socioeconomic Benefit to Individuals of Achieving the 2020 Targets for Five Preventive Chemotherapy Neglected Tropical Diseases
dc.contributor.authorRedekop W.K.
dc.contributor.authorLenk E.J.
dc.contributor.authorLuyendijk M.
dc.contributor.authorFitzpatrick C.
dc.contributor.authorNiessen L.
dc.contributor.authorStolk W.A.
dc.contributor.authorTediosi F.
dc.contributor.authorRijnsburger A.J.
dc.contributor.authorBakker R.
dc.contributor.authorHontelez J.A.C.
dc.contributor.authorRichardus J.H.
dc.contributor.authorJacobson J.
dc.contributor.authorde Vlas S.J.
dc.contributor.authorSeverens J.L.
dc.date.accessioned2019-11-08T06:45:25Z
dc.date.available2019-11-08T06:45:25Z
dc.date.issued2017
dc.identifier.citationRedekop W.K., Lenk E.J., Luyendijk M., Fitzpatrick C., Niessen L., Stolk W.A., Tediosi F., Rijnsburger A.J., Bakker R., Hontelez J.A.C., Richardus J.H., Jacobson J., de Vlas S.J., Severens J.L. (2017). The Socioeconomic Benefit to Individuals of Achieving the 2020 Targets for Five Preventive Chemotherapy Neglected Tropical Diseases. PLoS Neglected Tropical Diseases 11 (1) : e0005289. ScholarBank@NUS Repository. https://doi.org/10.1371/journal.pntd.0005289
dc.identifier.issn19352727
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/161900
dc.description.abstractBackground: Lymphatic filariasis (LF), onchocerciasis, schistosomiasis, soil-transmitted helminths (STH) and trachoma represent the five most prevalent neglected tropical diseases (NTDs). They can be controlled or eliminated by means of safe and cost-effective interventions delivered through programs of Mass Drug Administration (MDA)?also named Preventive Chemotherapy (PCT). The WHO defined targets for NTD control/elimination by 2020, reinforced by the 2012 London Declaration, which, if achieved, would result in dramatic health gains. We estimated the potential economic benefit of achieving these targets, focusing specifically on productivity and out-of-pocket payments. Methods: Productivity loss was calculated by combining disease frequency with productivity loss from the disease, from the perspective of affected individuals. Productivity gain was calculated by deducting the total loss expected in the target achievement scenario from the loss in a counterfactual scenario where it was assumed the pre-intervention situation in 1990 regarding NTDs would continue unabated until 2030. Economic benefits from out-of-pocket payments (OPPs) were calculated similarly. Benefits are reported in 2005 US$ (purchasing power parity-adjusted and discounted at 3% per annum from 2010). Sensitivity analyses were used to assess the influence of changes in input parameters. Results: The economic benefit from productivity gain was estimated to be I$251 billion in 2011?2020 and I$313 billion in 2021?2030, considerably greater than the total OPPs averted of I$0.72 billion and I$0.96 billion in the same periods. The net benefit is expected to be US$ 27.4 and US$ 42.8 for every dollar invested during the same periods. Impact varies between NTDs and regions, since it is determined by disease prevalence and extent of disease-related productivity loss. Conclusion: Achieving the PCT-NTD targets for 2020 will yield significant economic benefits to affected individuals. Despite large uncertainty, these benefits far exceed the investment required by governments and their development partners within all reasonable scenarios. Given the concentration of the NTDs among the poorest households, these investments represent good value for money in efforts to share the world?s prosperity and reduce inequity. ? 2017 Redekop et al.
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceUnpaywall 20191101
dc.subjectanemia
dc.subjectArticle
dc.subjectchemotherapy
dc.subjecthealth care cost
dc.subjecthuman
dc.subjecthydrocele
dc.subjectlymphatic filariasis
dc.subjectlymphedema
dc.subjectmajor clinical study
dc.subjectnonhuman
dc.subjectonchocerciasis
dc.subjectpopulation productivity
dc.subjectpremature mortality
dc.subjectschistosomiasis
dc.subjectsocioeconomics
dc.subjecttrachoma
dc.subjecttropical disease
dc.subjectchemoprophylaxis
dc.subjectcost benefit analysis
dc.subjecteconomics
dc.subjecthelminthiasis
dc.subjectNeglected Diseases
dc.subjectsocioeconomics
dc.subjecttropical medicine
dc.subjectanthelmintic agent
dc.subjectAnthelmintics
dc.subjectChemoprevention
dc.subjectCost-Benefit Analysis
dc.subjectHelminthiasis
dc.subjectHumans
dc.subjectNeglected Diseases
dc.subjectSocioeconomic Factors
dc.subjectTropical Medicine
dc.typeArticle
dc.contributor.departmentSAW SWEE HOCK SCHOOL OF PUBLIC HEALTH
dc.description.doi10.1371/journal.pntd.0005289
dc.description.sourcetitlePLoS Neglected Tropical Diseases
dc.description.volume11
dc.description.issue1
dc.description.pagee0005289
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_1371_journal_pntd_0005289.pdf1.94 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons